EXELIXIS INC (EXEL)
US30161Q1040 - Common Stock
Taking everything into account, EXEL scores 7 out of 10 in our fundamental rating. EXEL was compared to 565 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EXEL may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, EXEL could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
EXEL had positive earnings in the past year.
EXEL had a positive operating cash flow in the past year.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
EXEL has a better Return On Assets (15.77%) than 98.04% of its industry peers.
Looking at the Return On Equity, with a value of 20.52%, EXEL belongs to the top of the industry, outperforming 97.15% of the companies in the same industry.
EXEL's Return On Invested Capital of 18.78% is amongst the best of the industry. EXEL outperforms 97.50% of its industry peers.
EXEL had an Average Return On Invested Capital over the past 3 years of 7.03%. This is significantly below the industry average of 15.39%.
The last Return On Invested Capital (18.78%) for EXEL is above the 3 year average (7.03%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.77% | ||
| ROE | 20.52% | ||
| ROIC | 18.78% |
ROA(3y)7.28%
ROA(5y)8.82%
ROE(3y)8.99%
ROE(5y)10.39%
ROIC(3y)7.03%
ROIC(5y)8.48%
1.3 Margins
Looking at the Profit Margin, with a value of 22.43%, EXEL belongs to the top of the industry, outperforming 97.15% of the companies in the same industry.
EXEL's Profit Margin has declined in the last couple of years.
EXEL's Operating Margin of 29.22% is amongst the best of the industry. EXEL outperforms 98.04% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
With an excellent Gross Margin value of 96.25%, EXEL belongs to the best of the industry, outperforming 96.43% of the companies in the same industry.
In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.22% | ||
| PM (TTM) | 22.43% | ||
| GM | 96.25% |
OM growth 3Y-5.74%
OM growth 5Y-28.9%
PM growth 3Y0.09%
PM growth 5Y-32.47%
GM growth 3Y-0.1%
GM growth 5Y-0.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
EXEL has more shares outstanding than it did 5 years ago.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
EXEL has an Altman-Z score of 10.43. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.43, EXEL belongs to the top of the industry, outperforming 86.27% of the companies in the same industry.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 10.43 |
ROIC/WACC1.8
WACC10.41%
2.3 Liquidity
A Current Ratio of 3.93 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio (3.93) which is comparable to the rest of the industry.
EXEL has a Quick Ratio of 3.88. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL's Quick ratio of 3.88 is in line compared to the rest of the industry. EXEL outperforms 45.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.88 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 485.71%, which is quite impressive.
Measured over the past years, EXEL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.85% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.31%.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 16.47% on average per year.
EPS 1Y (TTM)485.71%
EPS 3Y22.28%
EPS 5Y-14.85%
EPS Q2Q%N/A
Revenue 1Y (TTM)17.31%
Revenue growth 3Y22.83%
Revenue growth 5Y16.47%
Sales Q2Q%14.33%
3.2 Future
The Earnings Per Share is expected to grow by 35.45% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.86% on average over the next years.
EPS Next Y174.15%
EPS Next 2Y64.62%
EPS Next 3Y52.75%
EPS Next 5Y35.45%
Revenue Next Year17.97%
Revenue Next 2Y9.45%
Revenue Next 3Y10.1%
Revenue Next 5Y7.86%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.01, EXEL is valued on the expensive side.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.54% of the companies are valued more expensively.
EXEL is valuated rather cheaply when we compare the Price/Earnings ratio to 28.53, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 19.86, the valuation of EXEL can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.01% of the companies listed in the same industry.
EXEL's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.01 | ||
| Fwd PE | 19.86 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.61% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.43% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.74 | ||
| EV/EBITDA | 12.14 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
EXEL's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y64.62%
EPS Next 3Y52.75%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXELIXIS INC
NASDAQ:EXEL (11/15/2024, 8:06:05 PM)
After market: 34.45 0 (0%)34.45
-0.6 (-1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.84B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.01 | ||
| Fwd PE | 19.86 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.77% | ||
| ROE | 20.52% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 29.22% | ||
| PM (TTM) | 22.43% | ||
| GM | 96.25% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)485.71%
EPS 3Y22.28%
EPS 5Y
EPS Q2Q%
EPS Next Y174.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)17.31%
Revenue growth 3Y22.83%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y